Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?

Giannis, Dimitrios; Douketis, James D; Spyropoulos, Alex C

Giannis, Dimitrios; Douketis, James D; Spyropoulos, Alex C.

Giannis D; Institute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Douketis JD; Department of Medicine, McMaster University, Hamilton, Ontario, Abbreviation.
Spyropoulos AC; Institute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA; Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Electronic address: aspyropoul@northwell.edu.

Eur J Intern Med ; 96: 13-16, 2022 02.

Article in English | MEDLINE | ID: covidwho-1605021

Subject(s)

COVID-19; Thrombosis; Anticoagulants; Humans; SARS-CoV-2

Keywords

Anticoagulant therapy; COVID-19; Thrombosis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombosis / COVID-19 Limits: Humans Language: English Journal: Eur J Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article Affiliation country: J.ejim.2021.11.003

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google